|
UGP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.13100006926948E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.34519999478644E-08 |
| Normal-vs-Stage2 |
5.140000E-03 |
| Normal-vs-Stage3 |
8.471500168028E-10 |
| Normal-vs-Stage4 |
4.81219508685626E-11 |
| Stage1-vs-Stage2 |
4.671600E-01 |
| Stage1-vs-Stage3 |
3.984200E-02 |
| Stage1-vs-Stage4 |
3.721500E-03 |
| Stage2-vs-Stage3 |
7.223600E-02 |
| Stage2-vs-Stage4 |
1.764240E-02 |
| Stage3-vs-Stage4 |
3.567400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.18139967095499E-11 |
| Normal-vs-AfricanAmerican |
2.797600E-04 |
| Normal-vs-Asian |
2.91570000365837E-08 |
| Caucasian-vs-AfricanAmerican |
4.979000E-01 |
| Caucasian-vs-Asian |
9.879400E-01 |
| AfricanAmerican-vs-Asian |
4.860000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.19760000051006E-07 |
| Normal-vs-Female |
3.22419979603694E-10 |
| Male-vs-Female |
5.572800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.17009999975626E-07 |
| Normal-vs-Age(41-60Yrs) |
3.07480041428221E-10 |
| Normal-vs-Age(61-80Yrs) |
2.3938000004442E-07 |
| Normal-vs-Age(81-100Yrs) |
2.400900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.165850E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.538800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.298800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.370200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.893800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.162200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.577000E-04 |
| Classical-VS-Follicular |
1.015900E-02 |
| Classical-VS-Other |
9.725800E-01 |
| Classical-VS-Normal |
1.97699967507958E-10 |
| Tall-VS-Follicular |
1.68739999999445E-05 |
| Tall-VS-Other |
4.159600E-01 |
| Tall-VS-Normal |
7.01072533360048E-12 |
| Follicular-VS-Other |
4.547600E-01 |
| Follicular-VS-Normal |
2.164100E-02 |
| Other-VS-Normal |
1.472990E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.59599999882687E-08 |
| Normal-vs-N1 |
7.88258347483861E-15 |
| N0-vs-N1 |
5.58689999999862E-05 |
|
|
